On Invalid Date, Acrivon Therapeutics (NASDAQ: ACRV) reported Q3 2023 earnings per share (EPS) of -$0.66, up 87.23% year over year. Total Acrivon Therapeutics earnings for the quarter were -$14.47 million. In the same quarter last year, Acrivon Therapeutics's earnings per share (EPS) was -$5.17.
As of Q1 2024, Acrivon Therapeutics's earnings has grown year over year. Acrivon Therapeutics's earnings in the past year totalled -$50.07 million.
What is ACRV's earnings date?
Acrivon Therapeutics's earnings date is Invalid Date. Add ACRV to your watchlist to be reminded of ACRV's next earnings announcement.
What was ACRV's revenue last quarter?
On Invalid Date, Acrivon Therapeutics (NASDAQ: ACRV) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Acrivon Therapeutics's revenue was $0.00.
What was ACRV's revenue growth in the past year?
As of Q1 2024, Acrivon Therapeutics's revenue has grown null year over year. Acrivon Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.